27
Jun
2023
Biopharma Has a Primary Care Problem
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Apr
2023
The “D” Word: Delivery is the Next Frontier for Genetic Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Feb
2023
Why Is It So Hard to Get Patients the Medicines They Need?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Oct
2022
Inflation Reduction Act: Big Changes Lurking for Drug Development
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Sep
2022
Seek Truth and Kill Quickly: Learning the Hard Way About Biotech Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Jun
2022
Lessons from the Road: What I Learned from Remix’s Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
May
2022
The Limits of Biomedical Innovation, and Why We Should Embrace Them
Last October, I wrote for this publication about the emergence of Antibody-Drug Conjugates (ADCs) for cancer, based on my father’s experience being treated with Padcev for bladder cancer. A few months later, I posted on Twitter that, while Padcev had stopped working for my father, he had since started on another ADC called Trodelvy. His tumors had shrunk. He was... Read More
7
Mar
2022
The Globally Integrated Biotech Is Down, But Not Out
“What else can you do? The entire isolation of Russia. Nowadays we see real solidarity of the whole world to cancel or stop any economic, cultural, technological, financial connections with Russia and we urge the same from the Drug Discovery community.” This was the message on Mar. 5 from Andrey Tolmachov, founder and CEO of Enamine Ltd., a Ukrainian chemistry... Read More
9
Feb
2022
Going Private: The Public Bear Market Will Soon Hit Private Companies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jan
2022
The Future is Simple: How the Genetic Revolution is Making Old Modalities Stronger
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Dec
2021
A Doctor’s View From the Front Line of the Omicron Wave
My phone buzzed with alerts about record-setting case numbers as I rushed between patients. A pile of tiny bottles with swabs floating in pink liquid accumulated while awaiting PCR testing. Patients with coughs and sniffles lined up outside the door, waiting to be seen. My shift as an internal medicine physician yesterday in MGH Chelsea’s urgent care facility reminded me... Read More
20
Oct
2021
ADCs: If at First You Don’t Succeed…
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Aug
2021
Is EQRx an Existential Threat to the Biopharma Industry?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Jul
2021
One-and-Done Gene Editing: A Feature or Flaw?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jun
2021
Learning from Mistakes in a Pandemic, Aspiring to Make Better Decisions Each Day
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Apr
2021
Diversity in Clinical Trials is in Everyone’s Interest
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Feb
2021
Big News for Obesity and Heart Failure That’s Been Underappreciated
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jan
2021
The Vaccine Rollout Could Prompt Real Reform to the US Health System
When I received the COVID vaccine on Dec 24, it was the end of a tense, frustrating two-week period. Thousands of healthcare workers like me — doctors, nurses, physician assistants and more — at the Mass General Brigham health system were eager to get vaccinated, and antsy about whether we’d get the shot as soon as it was available. The... Read More
17
Dec
2020
Round 2: What’s Changed and What Hasn’t in Caring for Outpatients with COVID-19
When one of my COVID patients called my cell phone a few weeks ago, my stomach dropped. “I feel worse,” she stammered. “I’m having more trouble catching my breath.” It was late morning on a Sunday. I was planning to take my son to the park, but after hearing those words, I knew this was not going to be a... Read More
11
Nov
2020
So You Have a Cool Platform. The Next Decision Will Make or Break Your Company
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.